Marc Hoffmann
A5007373641- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- HIV-related health complications and treatments
- Acute Lymphoblastic Leukemia research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- Biosimilars and Bioanalytical Methods
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS drug development and treatment
- COVID-19 Clinical Research Studies
- Breast Cancer Treatment Studies
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 and healthcare impacts
- Pharmacological Effects and Toxicity Studies
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Safe Handling of Antineoplastic Drugs
- Protein Degradation and Inhibitors
- Folate and B Vitamins Research
University of Kansas Medical Center
2016-2025
The University of Kansas Cancer Center
2016-2025
University of Basel
2024
University of Lausanne
2014-2023
University of Bern
2017-2023
University Hospital of Basel
2023
University Hospital of Bern
2023
Nuffield Orthopaedic Centre
2022
University of Oxford
2022
University of Zurich
2018-2022
Chimeric antigen receptor (CAR) T cell therapy is changing the paradigm in hematologic malignancies, but disparities access exist real-world setting. Efforts to address and eliminate these will ensure availability of this life-saving therapy. This study aimed determine patterns racial/ethnic distribution, socioeconomic strata, insurance coverage, travel time CAR recipients. We used Vizient Clinical Database (CDB) capture analyze elective encounters for administration as well any reason other...
Abstract Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim the NeoSTOP multisite randomized phase II trial was assess efficacy anthracycline-free anthracycline-containing neoadjuvant regimens. Patients Methods: aged ≥18 years with stage I–III TNBC were (1:1) receive either paclitaxel (P) weekly × 12 AUC6 every 21 days 4 followed...
Abstract Purpose: PIK3CA mutations are common in breast cancer and promote tumor progression treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel patients with HER2-negative metastatic (MBC). Patients Methods: Eligible had MBC any number prior chemotherapies. Phase I was 3+3 dose-escalation design three dose levels (250, 300, 350 mg) daily 100 mg/m2 administered on days 1, 8, 15 every 28 days. II according to Simon's two-stage...
Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells eliminate malignant B cells. In this phase 2, open-label study (NCT03677141), 40 (52.5% international prognostic index ≥3) previously untreated DLBCL initiated 6 cycles IV mosunetuzumab CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)...
Background Management of persistent low-level viraemia (pLLV) in patients on combined antiretroviral therapy (cART) with previously undetectable HIV viral loads (VLs) is challenging. We examined virological outcome and management among enrolled the Swiss Cohort Study (SHCS). Methods In this retrospective study (2000–2011), pLLV was defined as a VL 21–400 copies/ml ≥ three consecutive plasma samples ≥8 weeks between first last analyses, for ≥24 cART. Control had VLs over ≥32 weeks....
Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia or small lymphoma (CLL/SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are commercially available, and in many cases a lack of randomized clinical trial data makes selection optimal each patient challenging. Additionally, continue receive US, suggesting gap between guidelines real-world practice. The Lymphoma Research Foundation convened workshop...
Knowledge of the risk factors individuals with an asymptomatic sexually transmitted infection (STI) is essential for implementation targeted STI screening strategies.Between June 2015 and January 2017, was offered to all participants in Zurich Primary human immunodeficiency virus (HIV)-1 Infection study. Patients were tested gonorrhea, chlamydia, syphilis, hepatitis C (HCV).Of 214 participants, 174 (81%) screened at least once. Most patients men who have sex (MSM) (87.4%). Presenting a...
The durability of the antibody response to COVID-19 vaccines in patients with cancer undergoing treatment or who received a stem cell transplant is unknown and may be associated infection outcomes.To evaluate anti-SARS-CoV-2 spike protein receptor binding domain (anti-RBD) neutralizing (nAb) responses longitudinally over 6 months (SCT).In this prospective, observational, longitudinal cross-sectional study 453 an SCT at University Kansas Cancer Center City, blood samples were obtained before...
Abstract Background The Swiss HCVree Trial (NCT 02785666) was conducted in 2015–2017 with the goal of implementing a population-based systematic hepatitis C virus (HCV) micro-elimination program among men who have sex (MSM) human immunodeficiency (HIV) enrolled HIV Cohort Study (SHCS). trial led to 91% and 77% decline HCV prevalence incidence, respectively. long-term effect this is yet be explored. Methods All MSM SHCS were screened for RNA using stored plasma samples obtained 2019, termed...
PURPOSE In metastatic breast cancer (MBC), oral capecitabine prescribed at the US Food and Drug Administration (FDA)–approved dose of 1,250 mg/m 2 twice daily, 14 days on, 7 off, is associated with poor tolerance. Mathematical models suggest that a fixed-dose (FD), dose-dense schedule may optimize efficacy. We conducted randomized, open-label trial to compare efficacy tolerability FD capecitabine, 1,500 mg off (FD-7/7), FDA-approved (standard-dose [SD]-14/7). METHODS Females MBC any previous...
Abstract Background While chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment outcomes of relapsed/refractory hematological malignancies, this is associated with post‐treatment cytopenias, which can pose a challenge to its safe administration. This study describes management post‐CAR T cytopenias using thrombopoietin mimetic eltrombopag. Methods retrospective analysis included adult patients lymphoma or myeloma who received CAR at two academic medical centers....
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (reversible) BTKi, in patients with R/R malignancies (NCT03740529). Pirtobrutinib was investigated 127 at least one prior BTKi therapy absence progressive disease. most common adverse event (AE) leading discontinuation cardiac disorders (n=40, 31.5%),...
This Phase II study evaluated mosunetuzumab plus cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin (Pola-M-CHP) versus Pola-rituximab (R)-CHP for first-line treatment of diffuse large B-cell lymphoma (DLBCL). Patients were randomized 2:1 to receive 6 cycles Pola-M-CHP or Pola-R-CHP on Day 1 each 21-day cycle. Mosunetuzumab was administered intravenously via step-up dosing during Cycle at 30 mg subsequent cycles. The primary endpoint Independent Review Committee-assessed...
In human immunodeficiency virus (HIV)–infected individuals, the immune response over time to yellow fever vaccination (YFV) and necessity for booster are not well understood. We studied 247 participants of Swiss HIV Cohort Study (SHCS) with a first YFV after diagnosis determined their responses at 1 year, 5 years, 10 years postvaccination by plaque reduction neutralization titers (PRNTs) in stored blood samples. A PRNT 1:≥10 was regarded as reactive protective. Predictors were analyzed...
A 73-year-old female with past medical history of essential hypertension, hyperlipidemia, seasonal allergies, and chronic back pain presented to the hospital complaints headaches, fevers, fatigue, generalized body aches, shortness breath, diarrhea. Initial complete blood count was remarkable for leukopenia an absolute lymph 0.60 K/µL severe thrombocytopenia (platelet < 3 K/µL). She tested COVID-19 via nasopharyngeal swab polymerase chain reaction (PCR) testing found positive. Additional labs...